Cell Source CLCS Stock
Cell Source Price Chart
Cell Source CLCS Financial and Trading Overview
| Cell Source stock price | 0.5 USD |
| Previous Close | 0.4 USD |
| Open | 0.4 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.4 - 0.4 USD |
| 52 Week Range | 0.0003 - 1.5 USD |
| Volume | 153 USD |
| Avg. Volume | 4.14K USD |
| Market Cap | 13.99M USD |
| Beta (5Y Monthly) | -66.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CLCS Valuation Measures
| Enterprise Value | 21.11M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Cell Source Stock Price History
| Beta (5Y Monthly) | -66.05 |
| 52-Week Change | -99.93% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.5 USD |
| 52 Week Low | 0.0003 USD |
| 50-Day Moving Average | 0.1 USD |
| 200-Day Moving Average | 0.25 USD |
CLCS Share Statistics
| Avg. Volume (3 month) | 4.14K USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 35.25M |
| Float | 24.51M |
| Short Ratio | N/A |
| % Held by Insiders | 30.46% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2021 |
| Most Recent Quarter (mrq) | September 30, 2022 |
| Next Fiscal Year End | December 31, 2022 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -377.61% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -5812952 USD |
| Diluted EPS (ttm) | -0.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65.94K USD |
| Total Cash Per Share (mrq) | 0.002 USD |
| Total Debt (mrq) | 7.19M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.029 |
| Book Value Per Share (mrq) | -0.339 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2874615 USD |
| Levered Free Cash Flow (ttm) | -1112394 USD |
Profile of Cell Source
| Country | United States |
| State | NY |
| City | New York |
| Address | 57 West 57th Street |
| ZIP | 10019 |
| Phone | 646 416 7896 |
| Website | https://www.cell-source.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Q&A For Cell Source Stock
What is a current CLCS stock price?
Cell Source CLCS stock price today per share is 0.5 USD.
How to purchase Cell Source stock?
You can buy CLCS shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cell Source?
The stock symbol or ticker of Cell Source is CLCS.
Which industry does the Cell Source company belong to?
The Cell Source industry is Biotechnology.
How many shares does Cell Source have in circulation?
The max supply of Cell Source shares is 38.55M.
What is Cell Source Price to Earnings Ratio (PE Ratio)?
Cell Source PE Ratio is now.
What was Cell Source earnings per share over the trailing 12 months (TTM)?
Cell Source EPS is -0.18 USD over the trailing 12 months.
Which sector does the Cell Source company belong to?
The Cell Source sector is Healthcare.